Tyrosols and derivatives
Apexbio Technology LLC Verbascoside 61276-17-3 100mg
Verbascoside (CAS 61276-17-3) is a small-molecule inhibitor targeting protein kinase C (PKC) and the NF- B signaling pathway It is designed to modulate these pathways thereby regulating signal transduction and transcriptional activity in cellular responses Verbascoside exerts its biological activity primarily through the inhibition of PKC and suppression of NF- B DNA-binding activation In cell-based studies Verbascoside demonstrates inhibitory activity with an IC50 value of approximately 4 8 M in RANKL-treated RAW264 7 cells and bone marrow macrophages (BMMs) Based on these pharmacological properties Verbascoside holds research potential in the investigation of PKC/NF- B-mediated signaling osteoclastogenesis and related cell signaling mechanisms
Apexbio Technology LLC Verbascoside 61276-17-3 10mg
Verbascoside (CAS 61276-17-3) is a small-molecule inhibitor targeting protein kinase C (PKC) and the NF- B signaling pathway It is designed to modulate these pathways thereby regulating signal transduction and transcriptional activity in cellular responses Verbascoside exerts its biological activity primarily through the inhibition of PKC and suppression of NF- B DNA-binding activation In cell-based studies Verbascoside demonstrates inhibitory activity with an IC50 value of approximately 4 8 M in RANKL-treated RAW264 7 cells and bone marrow macrophages (BMMs) Based on these pharmacological properties Verbascoside holds research potential in the investigation of PKC/NF- B-mediated signaling osteoclastogenesis and related cell signaling mechanisms
Apexbio Technology LLC Verbascoside 61276-17-3 50mg
Verbascoside (CAS 61276-17-3) is a small-molecule inhibitor targeting protein kinase C (PKC) and the NF- B signaling pathway It is designed to modulate these pathways thereby regulating signal transduction and transcriptional activity in cellular responses Verbascoside exerts its biological activity primarily through the inhibition of PKC and suppression of NF- B DNA-binding activation In cell-based studies Verbascoside demonstrates inhibitory activity with an IC50 value of approximately 4 8 M in RANKL-treated RAW264 7 cells and bone marrow macrophages (BMMs) Based on these pharmacological properties Verbascoside holds research potential in the investigation of PKC/NF- B-mediated signaling osteoclastogenesis and related cell signaling mechanisms
Apexbio Technology LLC VX-702 479543-46-9; 745833-23-2 50mg
VX-702 is a small-molecule inhibitor targeting p38 mitogen-activated protein kinase (MAPK) also known as MAPK14 It is designed to inhibit p38 MAPK thereby regulating cellular responses to cytokine signaling and various stressors VX-702 exerts its biological activity primarily through ATP-competitive inhibition In experimental models VX-702 demonstrates potent inhibition with reported IC50 values ranging from 4 to 20 nM Based on these pharmacological properties VX-702 holds research potential in the study of p38 MAPK-dependent pathways platelet storage lesions and renal excretion mechanisms
Apexbio Technology LLC VX-702 479543-46-9; 745833-23-2 10mM (in 1mL DMSO)
VX-702 is a small-molecule inhibitor targeting p38 mitogen-activated protein kinase (MAPK) also known as MAPK14 It is designed to inhibit p38 MAPK thereby regulating cellular responses to cytokine signaling and various stressors VX-702 exerts its biological activity primarily through ATP-competitive inhibition In experimental models VX-702 demonstrates potent inhibition with reported IC50 values ranging from 4 to 20 nM Based on these pharmacological properties VX-702 holds research potential in the study of p38 MAPK-dependent pathways platelet storage lesions and renal excretion mechanisms
Apexbio Technology LLC VX-702 479543-46-9; 745833-23-2 25mg
VX-702 is a small-molecule inhibitor targeting p38 mitogen-activated protein kinase (MAPK) also known as MAPK14 It is designed to inhibit p38 MAPK thereby regulating cellular responses to cytokine signaling and various stressors VX-702 exerts its biological activity primarily through ATP-competitive inhibition In experimental models VX-702 demonstrates potent inhibition with reported IC50 values ranging from 4 to 20 nM Based on these pharmacological properties VX-702 holds research potential in the study of p38 MAPK-dependent pathways platelet storage lesions and renal excretion mechanisms
Apexbio Technology LLC VX-702 479543-46-9; 745833-23-2 100mg
VX-702 is a small-molecule inhibitor targeting p38 mitogen-activated protein kinase (MAPK) also known as MAPK14 It is designed to inhibit p38 MAPK thereby regulating cellular responses to cytokine signaling and various stressors VX-702 exerts its biological activity primarily through ATP-competitive inhibition In experimental models VX-702 demonstrates potent inhibition with reported IC50 values ranging from 4 to 20 nM Based on these pharmacological properties VX-702 holds research potential in the study of p38 MAPK-dependent pathways platelet storage lesions and renal excretion mechanisms
Apexbio Technology LLC VX-702 479543-46-9; 745833-23-2 200mg
VX-702 is a small-molecule inhibitor targeting p38 mitogen-activated protein kinase (MAPK) also known as MAPK14 It is designed to inhibit p38 MAPK thereby regulating cellular responses to cytokine signaling and various stressors VX-702 exerts its biological activity primarily through ATP-competitive inhibition In experimental models VX-702 demonstrates potent inhibition with reported IC50 values ranging from 4 to 20 nM Based on these pharmacological properties VX-702 holds research potential in the study of p38 MAPK-dependent pathways platelet storage lesions and renal excretion mechanisms